Abeona Therapeutics’ Post

Understanding open wounds like abrasions, lacerations, puncture wounds, and avulsions is essential for proper management and treatment. Let Gladiator Therapeutics help you on the road to recovery. Learn more about how our products aid in wound healing. https://ow.ly/Hq9Q50QhALB #GladiatorTherapeutics #FIR #Wounds #WoundCare #TypesOfWounds #WoundHealing

Did you know that a meniscus tear is one of the most common knee injuries, often resulting from sudden twists or pivots? Finding the right therapy equipment for recovery is crucial. Turn to Gladiator Therapeutics for a non-invasive, drug-free solution and discover why it's trusted by many on their road to recovery. https://ow.ly/Z9s450Sgaqk #GladiatorTherapeutics #Knee #KneePain #KneeInjury #KneeDevice #KneeTherapy #KneeTherapyEquipment

Weather affects more than just our plans. For those with carpal tunnel syndrome, high barometric pressure can add strain to the median nerve, leading to increased pain. Don’t let the weather disrupt your day—find relief with Gladiator Therapeutics. https://ow.ly/rSxk50SSqhF #GladiatorTherapeutics #CarpalTunnel #CarpalTunnelSyndrome #Wrist #WristPain #PainManagement

Don't forget to register your attendance to the FREE Webinar with MarketOpen Australia that is being held tomorrow, Wednesday 24th July over Zoom. Dr Liz Dallimore will be providing an update on our Phase 2 clinical trial program. Learn more through the post below ⬇️ #AGN #ASX #stroke #clinicaltrial #strokeawareness #lifescience #investorupdate

Each year in the United States, 185,000 individuals experience recurrent strokes. (1) 😱 Let's not just scroll past this number. Let's take action! Spread awareness, learn the warning signs, and prioritize preventive care. Every step counts in the fight against strokes! 💪💙 Find out how the rapid Genomadix CYP2C19 test can help optimize DAPT treatment to reduce recurrent stroke rates at www.genomadixcom (2,3)🧬#StrokeAwareness #PersonalizedMedicine #Pharmacogenetics 1. Kleindorfer DO, et al. Stroke. 2021;52:e364–e467. 2. Wang Y, et al. N Engl J Med. 2021;385:2520-2530. 3. Lee CR, et al. J Clinical Pharmacol Therapeutics. 2022;122(5):959-967.

JUST IN: Positive topline results from our Phase 3 BROOKLYN study of obicetrapib, our investigational CETP inhibitor, in patients with heterozygous familial hypercholesterolemia (HeFH). https://bit.ly/3LKFu3M

Today we are showing our support for International Tourette Syndrome (TS) Awareness Day. An estimated 1 in 100 people are affected by TS, and the associated tics can have a significant impact on quality of life and daily functioning. NTA aims to encourage a greater understanding of the condition while contributing to the development of better therapeutics through our conduct of clinical trials. #TouretteSyndrome #TouretteSyndromeAwarenessWeek #TouretteSyndromeAwareness #TouretteSyndromeAwarenessDay #ClinicalTrials #CRO #DrugDevelopment #NTA

As we approach the end of #WomensHealthMonth, we should continue focusing on uplifting women’s voices and better understand their real health care concerns. We’ve learned from the Patient Experience Survey that, too often, insurance barriers impact women and their ability to access the care they need, when they need it. Learn more below:

FDA’s approval of MIPLYFFA™ (arimoclomol) on Friday, September 20, was a watershed moment for the Niemann-Pick disease type C (NPC) community and for Zevra Therapeutics. MIPLYFFA™ is the first FDA-approved therapy for use in patients 2 years of age and older with this ultra-rare, relentlessly progressive, degenerative, and potentially fatal disease.  XOMA Royalty is entitled to receive a mid-single digit royalty on MIPLYFFA™ sales and up to $52.6 million in milestone payments. Our press release can be found here https://bit.ly/3XUjYk7. More detailed information on MIPLYFFA™ can be found in Zevra’s press release which is available here https://bit.ly/3XS9d1t. #NPC #NiemannPick #MIPLYFFA #arimoclomol #Royalties #Royalty #Milestones #NewDrugApproval #RareDisease 

Here is a 2.5 min video on what BlissGene Therapeutics is all about! With my team of 6 scientists, we will solve anxiety, depression, and pain. We’re about to go on Indiegogo!